EU indices positive this morning | TA focus on FLSmidth & Co


European stocks report | BP | Bayer | Novartis | FLSmidth & Co ...

Uptrend 2


Yesterday, European stocks rebounded. The Stoxx Europe 600 Index jumped 2.05%, Germany's DAX 30 surged 2.71%, France's CAC 40 rose 1.93%, and the U.K.'s FTSE 100 climbed 2.29%.

86% of STOXX 600 constituents traded higher yesterday.
43% of the shares trade above their 20D MA vs 28% Friday (below the 20D moving average).
48% of the shares trade above their 200D MA vs 44% Friday (below the 20D moving average).

The Euro Stoxx 50 Volatility index eased 0.91pt to 25.76, a new 52w high.

3mths relative high: Financial Services, Industrial
3mths relative low: Telecom.

Europe Best 3 sectors
automobiles & parts, media, construction & materials

Europe worst 3 sectors
real estate, food & beverage, telecommunications

The 10yr Bund yield rose 2bps to -0.52% (below its 20D MA). The 2yr-10yr yield spread rose 1bp to -17bps (above its 20D MA).

FR 07:45: Jun Budget Balance, exp.: E-117.9B
EC 10:00: Jun PPI YoY, exp.: -5%
EC 10:00: Jun PPI MoM, exp.: -0.6%

In Asian trading hours, major currencies rebounded against the U.S. dollar. EUR/USD climbed higher nearing 1.1770, GBP/USD was at elevated levels around 1.3075. USD/JPY managed to stay above 106.00. AUD/USD advanced to levels above 0.7130. As expected, Australia's central bank kept its key interest rate unchanged at 0.25%. Official data showed that Australia's June Retail Sales grew 2.7% on month (+2.4% expected) and Exports increased 3% (+4% expected).

Spot gold was little changed at $1,973 an ounce.

BP, oil major, announced 2Q results: "Underlying replacement cost loss for the quarter was 6.7 billion dollars, compared with a profit of 2.8 billion dollars for the same period a year earlier. The result was driven primarily by non-cash Upstream exploration write-offs - 6.5 billion dollars after tax (...) combined with the impact of lower oil and gas prices and very weak refining margins, reduced oil and gas production and much lower demand for fuels and lubricants. Oil trading delivered an exceptionally strong result. (...) A dividend of 5.25 cents per share was announced for the quarter, compared to 10.5 cents per share for the previous quarter."

Bayer, a German healthcare giant, said it swung to a 2Q net loss of 9.55 billion euros from a net income of 404 million euros in the prior-year period, citing net special charges of 12.51 billion euros. 2Q EBITDA before special items increased 5.6% on year to 2.88 billion euros on sales of 10.05 billion euros, up 2.5% on a currency- and portfolio-adjusted basis. The Company lowered its forecast on full-year EBITDA before special items to 12.1 billion euros from 12.3-12.6 billion euros previously and that on Core earnings per share to 6.70-6.90 euros from 7.00-7.20 euros.

Hugo Boss, a German premium-apparel company, announced that it swung to a 2Q net loss of 186 million euros from a net income of 52 million euros in the prior-year period on sales of 275 million euros, down 59% on year. The Company said: "Retail sales trends during the second quarter have shown a sequential improvement month by month. This positive trend has also continued so far in Q3, as HUGO BOSS has recorded further improvements in its global retail operations during the month of July."

Fraport, the operator of Frankfurt airport, posted a 1H net loss of 231 million euros, compared with a net income of 165 million euros in the prior-year period on revenue of 911 million euros, down 49% on year. The Company pointed out: "Frankfurt Airport's passenger traffic plummeted by 94.4% year-on-year in the April-to-June 2020 period, while falling by a total of 63.8% during the entire first half."

Infineon Technologies, a semiconductors maker, reported that it swung to a 3Q net loss of 128 million euros from a net income of 224 million euros in the prior-year period.

DSM, a Dutch nutrition and health company, reported that 1H net income fell to 270 million euros from 401 million euros in the prior-year period. 1H Adjusted EBITDA eased 4.3% on year to 825 million euros on sales of 4.53 billion euros, slightly lower than 4.57 billion euros a year earlier.

Novartis, a Swiss maker of pharmaceutical products, reported positive results from a Phase 2 trial of Kymriah (tisagenlecleucel) in patients with relapsed or refractory follicular lymphoma.

FLSmidth & Co, a machinery firm, reported that 2Q EBITA decreased 73% on year to 131 million Danish Krone on revenue of 3.85 billion Danish Krone, down 30%. The Company said: "The clear majority of the revenue decline was attributable to COVID-19, but the change was also a result of a lower backlog entering the year."
From a weekly point of view, the stock remains within a bearish channel since June 2018. Below 214.7 krone, targets are set at 170 Krone and 134.30 krone in extension.

Source: GAIN Capital, TradingView

More from Equities

Disclaimer: The information on this web site is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement. The information and opinions in this report are for general information use only and are not intended as an offer or solicitation with respect to the purchase or sale of any currency or CFD contract. All opinions and information contained in this report are subject to change without notice. This report has been prepared without regard to the specific investment objectives, financial situation and needs of any particular recipient. Any references to historical price movements or levels is informational based on our analysis and we do not represent or warranty that any such movements or levels are likely to reoccur in the future. While the information contained herein was obtained from sources believed to be reliable, author does not guarantee its accuracy or completeness, nor does author assume any liability for any direct, indirect or consequential loss that may result from the reliance by any person upon any such information or opinions.

Futures, Options on Futures, Foreign Exchange and other leveraged products involves significant risk of loss and is not suitable for all investors. Losses can exceed your deposits. Increasing leverage increases risk. Spot Gold and Silver contracts are not subject to regulation under the U.S. Commodity Exchange Act. Contracts for Difference (CFDs) are not available for US residents. Before deciding to trade forex and commodity futures, you should carefully consider your financial objectives, level of experience and risk appetite. Any opinions, news, research, analyses, prices or other information contained herein is intended as general information about the subject matter covered and is provided with the understanding that we do not provide any investment, legal, or tax advice. You should consult with appropriate counsel or other advisors on all investment, legal, or tax matters. References to or GAIN Capital refer to GAIN Capital Holdings Inc. and its subsidiaries. Please read Characteristics and Risks of Standardized Options.

Open an Account